Join the SmallCapReview mailing list





Intercept Pharmaceuticals (Nasdaq: ICPT)

A biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases utilizing its expertise in bile acid chemistry. 

The company's lead product candidate, obeticholic acid, is a bile acid analog and first-in-class agonist of the farnesoid X receptor. OCA is being developed for a variety of chronic liver diseases including NASH, primary biliary cirrhosis, portal hypertension and bile acid diarrhea. 

OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and China.

More on ICPT